Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Biogen CEO Michel Vounatsos to step aside as Aduhelm sales continue to sputter

By Brian Buntz | May 3, 2022

BiogenWith the blockbuster dreams of the Alzheimer’s drug Aduhelm (aducanumab) dashed for the foreseeable future, Biogen has announced that its CEO Michel Vounatsos will depart.

Vounatsos began his tenure as CEO in 2017.

Vounatsos’ plans to exit the company came out on the same day that Biogen reported Q1 adjusted earnings per share of $3.62, 76¢ behind the $4.38 that analysts expected. The 76¢ amount was equal to the negative impact that Biogen reported to Aduhelm inventory write-offs.

Revenue was $2.532 billion for the quarter ended March 31, 2022, down 6% from Q1 2021.

The company’s decision to pursue the FDA approval of Aduhelm after two Phase 3 trials failed to show a clear benefit proved controversial.

Michel Vounatsos

Michel Vounatsos [Image courtesy of Biogen]

Although the company would eventually win approval of Aduhelm in June 2021 under the accelerated approval program, the drug faced a string of setbacks afterward. Many physicians refused to prescribe it. In 2021, sales of the drug were just $3 million. In April 2022, CMS concluded that it would restrict coverage of Aduhelm to clinical trial participants. Later in the month, Biogen announced it would stop seeking European approval for aducanumab.

In its Q1 earnings call, the company announced it would “substantially” eliminate the commercial team in place to sell Aduhelm. Biogen projected that restructuring would lead to an estimated $500 million in annualized savings. The company had already announced prior initiatives to save an additional $500 million.

In January, Biogen announced its plans to sell an equity stake in Samsung Bioepis worth another $2.3 billion.

The company continues to study Aduhelm, including in the Phase 4 post-marketing requirement trial ENVISION.

Biogen also continues to develop another Alzheimer’s drug candidate known as lecanemab, which is currently the subject of the Phase 3 ClarityAD study.

Biogen collaborated with Eisai on the development of Aduhelm and lecanemab.

The company is also pursuing FDA approval of the antidepressant zuranolone for major depressive disorder.

Biogen’s quarterly revenue of $2.5 billion trailed the nearly $2.7 billion it earned in the same period last year.

Sales of its multiple sclerosis franchise, the spinal muscular atrophy drug Spinraza and biosimilars were all down.
In mid-day trading, BIIB shares were up about 1% to $209.45.

 


Filed Under: Drug Discovery and Development, Neurological Disease
Tagged With: Aducanumab, Aduhelm, Biogen, Michel Vounatsos
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE